- Home
- ILLR vs ETON Comparison
ILLR vs ETON Comparison
Compare ILLR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ETON
- Stock Information
- Founded
- ILLR 2015
- ETON 2017
- Country
- ILLR United States
- ETON United States
- Employees
- ILLR N/A
- ETON N/A
- Industry
- ILLR Investment Managers
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ETON Health Care
- Exchange
- ILLR Nasdaq
- ETON Nasdaq
- Market Cap
- ILLR 79.7M
- ETON 388.3M
- IPO Year
- ILLR N/A
- ETON 2018
- Fundamental
- Price
- ILLR $0.69
- ETON $17.65
- Analyst Decision
- ILLR
- ETON Strong Buy
- Analyst Count
- ILLR 0
- ETON 3
- Target Price
- ILLR N/A
- ETON $29.67
- AVG Volume (30 Days)
- ILLR 3.8M
- ETON 223.3K
- Earning Date
- ILLR 09-19-2025
- ETON 11-11-2025
- Dividend Yield
- ILLR N/A
- ETON N/A
- EPS Growth
- ILLR N/A
- ETON N/A
- EPS
- ILLR N/A
- ETON N/A
- Revenue
- ILLR $45,244,000.00
- ETON $58,181,000.00
- Revenue This Year
- ILLR N/A
- ETON $105.25
- Revenue Next Year
- ILLR N/A
- ETON $40.84
- P/E Ratio
- ILLR N/A
- ETON N/A
- Revenue Growth
- ILLR N/A
- ETON 85.40
- 52 Week Low
- ILLR $0.40
- ETON $4.79
- 52 Week High
- ILLR $6.52
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- ILLR 62.81
- ETON 60.07
- Support Level
- ILLR $0.41
- ETON $17.22
- Resistance Level
- ILLR $0.76
- ETON $18.06
- Average True Range (ATR)
- ILLR 0.09
- ETON 0.63
- MACD
- ILLR 0.03
- ETON -0.05
- Stochastic Oscillator
- ILLR 70.08
- ETON 59.26
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.